BFRGW

distress 7/10 · high distress / dilution risk

$0.14+43%today-19% from 52w high

Revenue

pre-revenue

Liquidity

$5M

Runway

1.0 yrs

Shares 1y

+84%

Price & events

+3.6% over 6M

CatalystRating changeDilutionFinancingdashed = today

+43.4%

+0.0%

—

+3.6%

All

Overview

Market Cap: $2.69M
Volume: 0
52 Week Range: $0.10 – $0.18
Total Shares: 18.54M

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 4

2026-03-30partnershipCommercial feasibility agreement with top 5 global pharma to identify drug targets in major depressive disorder using bfLEAP, includes milestone payments and option for exclusive rightsSEC 8-K
2026-03-27partnershipFeasibility agreement with global pharma to use bfLEAP for MDD target discovery; milestone payments and exclusive option.SEC 8-K
2026-03-01fda agreementLaunch of bfARENAS platform, completing end-to-end AI platform for pharma R&DSEC 8-K
2025-06-12partnershipCollaboration with Sygnature Discovery to introduce BullFrog Data Networks to global biopharma clients; expected to generate $15-30M revenue through 2028.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 18,541,651 · 4 offerings/1y · 1 PIPEs

2026-07-06424B3offering
2026-06-10EFFECTshelf_effective
2026-05-29S-1shelf_registration
2026-04-01424B5offering
2026-03-308-Kmaterial_agreement
2025-12-01424B3offering
2025-11-25EFFECTshelf_effective

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors

none identified